Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Assay Kit / ADA/PK Assay Elisa Kit

Anti-Nivolumab Neutralizing Antibody ELISA kit

Catalog #:   KAH02252 Specific References (13) DATASHEET
Sample type: Plasma, Serum
Range: 15.625-1,000 ng/ml
Overview

Catalog No.

KAH02252

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

15.625-1,000 ng/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

BMS-936558,MDX-1106,ONO-4538, CAS: 946414-94-4

Data Image
References

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours., PMID:39663448

The impact of the expression level of growth differentiation factor 15 in tumor tissue on the response to immunotherapy in non-small cell lung cancer., PMID:39103762

Immunotherapies for advanced hepatocellular carcinoma., PMID:37025485

Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy., PMID:36857433

The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model., PMID:36077380

Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays., PMID:34608545

Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer., PMID:34253638

Advances in immunotherapy for hepatocellular carcinoma., PMID:33850328

COVID-19 and Kidney Disease: Molecular Determinants and Clinical Implications in Renal Cancer., PMID:32540268

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit., PMID:31402780

Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma., PMID:29959458

Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors., PMID:27557786

Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential., PMID:26098609

Datasheet
$ 2200
Product specifications
96 T 2200

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Nivolumab Neutralizing Antibody ELISA kit [KAH02252]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only